The European Commission approved Zynquista (sotagliflozin) as a new treatment for people with type 1 diabetes. Zynquista is an oral tablet which prevents the SGLT-1 and SGLT-2 proteins that impact how the intestines and kidneys absorb and glucose that will result in better diabetes control. Sanofi is collaborating ...
Find MoreLive Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!